Focus on Equities that offer Growth,
Value and Strong Potential Return
Friday, November 27, 2015
Sarepta Therapeutics, Inc.
In-Depth Research Report Available for SRPT
Not a Member?
No problem! Take a moment to
activate your FREE account here:
Company Profile SRPT
On October 1st, the company announced a four year collaborative research agreement to establish the Sarepta Translational Laboratory with Murdoch University, Perth, Western Australia. The Laboratory, led by Murdoch University professors Steve Wilton, Ph.D. and Sue Fletcher, Ph.D., will explore the applicability of the Company’s phosphorodiamidate morpholino oligomer (PMO) technology for disease targets beyond Duchenne muscular dystrophy (DMD), such as cystic fibrosis and spinal muscular atrophy.
Going forward ... (see research report)